AU598853B2 - Therapeutic composition comprising gamma-linolenic acid and calcium - Google Patents

Therapeutic composition comprising gamma-linolenic acid and calcium Download PDF

Info

Publication number: AU598853B2
Authority: AU; Australia
Prior art keywords: calcium; gla; gamma; linolenic acid; doses
Prior art date: 1986-09-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU77938/87A

Other languages

English (en)

Other versions

AU7793887A (en

Inventor

David Frederick Horrobin

Y. Sheng Huang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Scotia Holdings PLC

Original Assignee

Efamol Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-09-10

Filing date

1987-09-02

Publication date

1990-07-05

1987-09-02 Application filed by Efamol Ltd filed Critical Efamol Ltd

1988-03-17 Publication of AU7793887A publication Critical patent/AU7793887A/en

1990-07-05 Application granted granted Critical

1990-07-05 Publication of AU598853B2 publication Critical patent/AU598853B2/en

1995-07-27 Assigned to SCOTIA HOLDINGS PLC reassignment SCOTIA HOLDINGS PLC Alteration of Name(s) in Register under S187 Assignors: EFAMOL LIMITED

2007-09-02 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

235000020664 gamma-linolenic acid Nutrition 0.000 title claims abstract description 42
VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 title claims abstract description 41
VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 title claims abstract description 39
229960002733 gamolenic acid Drugs 0.000 title claims abstract description 39
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 36
239000011575 calcium Substances 0.000 title claims abstract description 36
229910052791 calcium Inorganic materials 0.000 title claims abstract description 36
239000000203 mixture Substances 0.000 title description 10
230000001225 therapeutic effect Effects 0.000 title description 3
208000001132 Osteoporosis Diseases 0.000 claims abstract description 6
208000020084 Bone disease Diseases 0.000 claims abstract description 5
206010020772 Hypertension Diseases 0.000 claims abstract description 5
206010036618 Premenstrual syndrome Diseases 0.000 claims abstract description 5
210000000988 bone and bone Anatomy 0.000 claims abstract description 5
238000000034 method Methods 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
239000003814 drug Substances 0.000 claims description 3
229960005069 calcium Drugs 0.000 description 24
HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 15
235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 15
HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 15
239000003921 oil Substances 0.000 description 12
235000019198 oils Nutrition 0.000 description 12
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 10
239000002253 acid Substances 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 6
229910000019 calcium carbonate Inorganic materials 0.000 description 5
229960003563 calcium carbonate Drugs 0.000 description 5
239000002775 capsule Substances 0.000 description 5
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
230000002950 deficient Effects 0.000 description 4
235000005911 diet Nutrition 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
235000004626 essential fatty acids Nutrition 0.000 description 4
235000008524 evening primrose extract Nutrition 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
239000002243 precursor Substances 0.000 description 4
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical class C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 3
241000219925 Oenothera Species 0.000 description 3
239000004227 calcium gluconate Substances 0.000 description 3
229960004494 calcium gluconate Drugs 0.000 description 3
235000013927 calcium gluconate Nutrition 0.000 description 3
NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 3
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
229940089020 evening primrose oil Drugs 0.000 description 3
239000010475 evening primrose oil Substances 0.000 description 3
239000000284 extract Substances 0.000 description 3
235000020778 linoleic acid Nutrition 0.000 description 3
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
150000003180 prostaglandins Chemical class 0.000 description 3
240000004355 Borago officinalis Species 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000011149 active material Substances 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000013256 coordination polymer Substances 0.000 description 2
230000037213 diet Effects 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
235000007689 Borago officinalis Nutrition 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
240000008916 Oenothera biennis Species 0.000 description 1
235000004496 Oenothera biennis Nutrition 0.000 description 1
241000179990 Oenothera lamarckiana Species 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
229940087168 alpha tocopherol Drugs 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical class CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
229960002713 calcium chloride Drugs 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229960002283 calcium glubionate Drugs 0.000 description 1
YPCRNBPOUVJVMU-LCGAVOCYSA-L calcium glubionate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YPCRNBPOUVJVMU-LCGAVOCYSA-L 0.000 description 1
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
239000001527 calcium lactate Substances 0.000 description 1
229960002401 calcium lactate Drugs 0.000 description 1
235000011086 calcium lactate Nutrition 0.000 description 1
229940078480 calcium levulinate Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
229960001714 calcium phosphate Drugs 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
-1 cholesteryl ester Chemical class 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000010411 cooking Methods 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940045761 evening primrose extract Drugs 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
229940066963 gamma-linolenate Drugs 0.000 description 1
238000001030 gas--liquid chromatography Methods 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229940049918 linoleate Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
235000013310 margarine Nutrition 0.000 description 1
239000003264 margarine Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
230000003019 stabilising effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000002076 α-tocopherol Substances 0.000 description 1
235000004835 α-tocopherol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Natural Medicines & Medicinal Plants (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Botany (AREA)
Medical Informatics (AREA)
Mycology (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Steroid Compounds (AREA)

AU77938/87A 1986-09-10 1987-09-02 Therapeutic composition comprising gamma-linolenic acid and calcium Ceased AU598853B2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8621816		1986-09-10
GB868621816A GB8621816D0 (en)	1986-09-10	1986-09-10	Therapeutic composition

Publications (2)

Publication Number	Publication Date
AU7793887A AU7793887A (en)	1988-03-17
AU598853B2 true AU598853B2 (en)	1990-07-05

Family

ID=10603976

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU77938/87A Ceased AU598853B2 (en)	1986-09-10	1987-09-02	Therapeutic composition comprising gamma-linolenic acid and calcium

Country Status (16)

Country	Link
US (1)	US4855136A (ko)
EP (1)	EP0261814B1 (ko)
JP (1)	JP2775627B2 (ko)
KR (1)	KR970002608B1 (ko)
AT (1)	ATE69166T1 (ko)
AU (1)	AU598853B2 (ko)
CA (1)	CA1289887C (ko)
DE (1)	DE3774382D1 (ko)
ES (1)	ES2044947T4 (ko)
FI (1)	FI873905A (ko)
GB (1)	GB8621816D0 (ko)
GR (1)	GR3003153T3 (ko)
HK (1)	HK129493A (ko)
IE (1)	IE60418B1 (ko)
SG (1)	SG115093G (ko)
ZA (1)	ZA876483B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9012651D0 (en) *	1990-06-06	1990-07-25	Efamol Holdings	Essential fatty acid treatment
GB2254556B (en) *	1991-04-11	1995-04-12	Fisons Plc	Formulations containing linolenic acid
GB9112052D0 (en) *	1991-06-05	1991-07-24	Efamol Holdings	Fatty acid treatment
US5888541A (en) *	1992-08-21	1999-03-30	Scotia Holdings Plc	Fatty acid treatment
US5516801A (en) *	1992-08-21	1996-05-14	Scotia Holdings Plc	Fatty acid treatment for ectopic calcium deposition
GB9217780D0 (en) *	1992-08-21	1992-10-07	Efamol Holdings	Fatty acid treatment
DE4240713C1 (de) *	1992-12-03	1994-01-27	Georg Prof Dr Dietz	Verwendung eines Gemischs aus Calciumhydroxid und Oleum pedum tauri zur Kollageneubildung in vivo
DE4330664A1 (de) *	1993-09-10	1995-03-16	Beiersdorf Ag	Verwendungen von Pflanzenölen
EP0711503A3 (en) *	1994-11-14	1997-11-26	Scotia Holdings Plc	Milk fortified with GLA and/or DGLA
US5804210A (en) *	1996-08-07	1998-09-08	Wisconsin Alumni Research Foundation	Methods of treating animals to maintain or enhance bone mineral content and compositions for use therein
JP4129566B2 (ja)	1997-09-05	2008-08-06	大塚製薬株式会社	肝臓脂肪蓄積抑制組成物及び肝臓脂肪蓄積抑制用食品添加剤
US6451771B1 (en)	1999-02-12	2002-09-17	Nutramax Laboratories, Inc.	Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
US20070141181A1 (en)	1998-02-13	2007-06-21	Nutramax Laboratories, Inc.	Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6797289B2 (en)	1998-02-13	2004-09-28	Nutramax Laboratories, Inc.	Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6479545B1 (en) *	1999-09-30	2002-11-12	Drugtech Corporation	Formulation for menopausal women
CN1259044C (zh)	2001-03-30	2006-06-14	日清奥利友集团株式会社	骨代谢改善剂
MXPA03010467A (es) *	2001-05-14	2004-12-06	Martek Biosciences Boulder Corp	Produccion y uso de una fraccion polar rica en lipidos que contienen acido estearidonico y acido gama-linolenico proviniente de semillas y microbios.
CA2436650A1 (en) *	2003-08-06	2005-02-06	Naturia Inc.	Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
US8728546B1 (en) *	2013-03-15	2014-05-20	Swing Aerobics Licensing, Inc.	Medicament for treatment of cancer, cardiovascular diseases and inflammation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4799885A (en) *	1984-10-03	1986-04-10	Scotia Holdings Plc	Compositions of copper and fatty acids

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3075880A (en) *	1961-03-29	1963-01-29	Roth Lester Hugh	Bone and tissue repair
US4273763A (en) *	1978-01-23	1981-06-16	Efamol Limited	Pharmaceutical and dietary compositions
IE47777B1 (en) *	1978-01-23	1984-06-13	Efamol Ltd	Pharmaceutical and dietary composition comprising gamma-linolenic acids
IE49783B1 (en) *	1979-05-18	1985-12-11	Efamol Ltd	Pharmaceutical and dietary composition comprising epsilon-linolenic acids
US4421743A (en) *	1979-09-14	1983-12-20	T & R Chemicals, Inc.	Antihypertension treatment
FR2490631A1 (fr) *	1980-09-24	1982-03-26	Roussel Uclaf	Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique
US4642317B1 (en) *	1981-06-16	1996-12-31	Ohio Agricultural Res & Dev	Process for feeding ruminant animals and composition for use therein
EP0092076B1 (fr) *	1982-04-16	1986-12-17	Societe Des Produits Nestle S.A.	Composition lipidique destinée à l'alimentation orale, entérale ou parentérale
DE3346525A1 (de) *	1983-12-22	1985-07-04	A. Nattermann & Cie GmbH, 5000 Köln	Pharmazeutische zubereitung mit speziellen 1,2-diacyl-glycero-3-phosphocholinen zur behandlung von erkrankungen im magen-darmbereich
US4695590A (en) *	1986-05-05	1987-09-22	California Health Technologies	Method for retarding aging

1986
- 1986-09-10 GB GB868621816A patent/GB8621816D0/en active Pending
1987
- 1987-08-28 ES ES87307653T patent/ES2044947T4/es not_active Expired - Lifetime
- 1987-08-28 AT AT87307653T patent/ATE69166T1/de not_active IP Right Cessation
- 1987-08-28 DE DE8787307653T patent/DE3774382D1/de not_active Expired - Fee Related
- 1987-08-28 EP EP87307653A patent/EP0261814B1/en not_active Expired - Lifetime
- 1987-08-31 IE IE233387A patent/IE60418B1/en not_active IP Right Cessation
- 1987-08-31 ZA ZA876483A patent/ZA876483B/xx unknown
- 1987-09-02 US US07/092,191 patent/US4855136A/en not_active Expired - Lifetime
- 1987-09-02 AU AU77938/87A patent/AU598853B2/en not_active Ceased
- 1987-09-09 CA CA000546439A patent/CA1289887C/en not_active Expired - Fee Related
- 1987-09-09 KR KR1019870009971A patent/KR970002608B1/ko not_active IP Right Cessation
- 1987-09-09 FI FI873905A patent/FI873905A/fi not_active Application Discontinuation
- 1987-09-10 JP JP62225467A patent/JP2775627B2/ja not_active Expired - Lifetime
1991
- 1991-11-19 GR GR91401777T patent/GR3003153T3/el unknown
1993
- 1993-10-18 SG SG115093A patent/SG115093G/en unknown
- 1993-11-25 HK HK1294/93A patent/HK129493A/xx not_active IP Right Cessation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4799885A (en) *	1984-10-03	1986-04-10	Scotia Holdings Plc	Compositions of copper and fatty acids

Also Published As

Publication number	Publication date
AU7793887A (en)	1988-03-17
IE60418B1 (en)	1994-07-13
SG115093G (en)	1994-01-21
FI873905A (fi)	1988-03-11
ES2044947T4 (es)	1996-07-16
DE3774382D1 (de)	1991-12-12
EP0261814B1 (en)	1991-11-06
IE872333L (en)	1988-03-10
JP2775627B2 (ja)	1998-07-16
ATE69166T1 (de)	1991-11-15
ES2044947T3 (es)	1994-01-16
HK129493A (en)	1993-12-03
FI873905A0 (fi)	1987-09-09
ZA876483B (en)	1989-08-30
CA1289887C (en)	1991-10-01
KR880003620A (ko)	1988-05-28
EP0261814A2 (en)	1988-03-30
GR3003153T3 (en)	1993-02-17
EP0261814A3 (en)	1989-02-01
GB8621816D0 (en)	1986-10-15
JPS6377817A (ja)	1988-04-08
KR970002608B1 (ko)	1997-03-06
US4855136A (en)	1989-08-08

Legal Events

Date	Code	Title	Description
2000-04-06	MK14	Patent ceased section 143(a) (annual fees not paid) or expired

Publication	Publication Date	Title
AU598853B2 (en)	1990-07-05	Therapeutic composition comprising gamma-linolenic acid and calcium
EP0347056B1 (en)	1993-04-07	Essential fatty acid compositions
EP0440341B1 (en)	1993-12-08	EFA compositions and therapy
US5198468A (en)	1993-03-30	Essential fatty acid composition
EP0222483B1 (en)	1992-03-18	Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of endometriosis
US4970076A (en)	1990-11-13	Fatty acid composition
EP0524796B1 (en)	1995-04-12	Use of essential fatty acids in the preparation of a medicament for the treatment of AIDS
EP0296751B1 (en)	1992-10-14	Essential fatty acid compositions
EP0585026A1 (en)	1994-03-02	Use of fatty acids for increasing gut calcium absorption
JPH06128154A (ja)	1994-05-10	食品組成物
EP0093516B1 (en)	1986-10-01	Pharmaceutical composition
US4965075A (en)	1990-10-23	Methods of increasing 1-series PGs in the body
EP0416743B1 (en)	1995-06-21	Antivirale Verwendung von Zusammensetzungen bestehend aus EFAs und Interferon
EP0246734B1 (en)	1991-01-30	Iron-containing composition and method for treatment of cancer
EP0087865B1 (en)	1986-10-01	Pharmaceutical composition
EP0201159B1 (en)	1992-04-29	Pharmaceutical and dietary compositions containing linolenic acids for the treatment of benign prostatic hypertrophy
EP0416855B1 (en)	1993-12-08	Fatty acids for the treatment and prevention of skin damage caused by radiotherapy
EP0440347B1 (en)	1993-09-08	Essential fatty acid compositions for increasing the fat content of mammalian milk